Metabolic syndrome: What are the risks for humans?

BioScience Trends

Volumn 4, Issue 5, 2010, Pages 204-212

  Gupta, Abhishek ^a   Gupta, Vani ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Health; Human; Metabolic syndrome (MeTs)

Indexed keywords

AGE; BODY MASS; CARDIOVASCULAR DISEASE; DIET; EXERCISE; HISTORY; HUMAN; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RACE; REVIEW; RISK FACTOR;

AGE FACTORS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; METABOLIC SYNDROME X; RISK FACTORS;

EID: 79952276408     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008; 28:629-636.
2. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: Prevalence in worldwide populations. Endocrinol Metab Clin North Am. 2004; 33:351-375.
3. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004; 27:2444-2449.
4. Alberti KG, Zimmet PZ. Should we dump the metabolic syndrome? No. BMJ. 2008; 336:641.
5. Nesto RW. The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Med. 2003; 4 (SUPPL 6):S11-S18.
6. Joslin EP. The prevention of diabetes mellitus. JAMA. 1921; 76:79-84.
7. Kylin E. Studies of the hypertension-hyperglycemiahyperuricemia syndrome. Zentralbl Inn Med. 1923; 44:105-127. (in German)
8. Vague J. La differentiation sexually, factor determinant des formes de l'ob sit. Presse Med. 1947; 30:339-340. (in French)
9. Avogaro P, Crepaldi G, Enzi G, Tiengo A. Associazione di iperlipidemia, diabete mellito e obesità di medio grado. Acta Diabetol Lat. 1967; 4:572-590. (in Italian)
10. Haller H. Epidemiology and associated risk factors of hyperlipoproteinemia. Z Gesamte Inn Med. 1977; 32:124-128. (in German)
11. Singer P. Diagnosis of primary hyperlipoproteinemias. Z Gesamte Inn Med. 1977; 32:129-133. (in German)
12. Phillips GB. Sex hormones, riskfactors and cardiovascular disease. Am J Med. 1978; 65:7-11.
13. Phillips GB. Relationship between serum sex hormones and glucose, insulin, and lipid abnormalities in men with myocardial infarction. Proc Natl Acad Sci U S A. 1977; 74:1729-1733.
14. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988; 37:1595-1607.
15. World Health Organization (WHO). Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation, 1999.
16. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection and treatment of high blood cholesterol in adults (adult treatment Pannel III). JAMA. 2001; 285:2486-2497.
17. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999; 16:442-443.
18. The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf (accessed March 5, 2010).
19. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112:2735-2752.
20. The American Heart Association's description of Syndrome X. http://www.americanheart.org/metabolic syndrome (accessed March 5, 2010).
21. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - A new worldwide definition. Lancet. 2005; 366:1059-1062.
22. Florez H, Silva E, Fernández V, Ryder E, Sulbarán T,Campos G, Calmón G, Clavel E, Castillo-Florez S, Goldberg R. Prevalence and risk factors associated with the metabolic syndrome and dyslipidaemia in White, Black, Amerindian and Mixed Hispanics in Zulia State, Venezuela. Diabetes Res Clin Pract. 2005; 69:63-77.
23. Marquezine GF, Oliveira CM, Pereira AC, Krieger JE, Mill JG. Metabolic syndrome determinants in an urban population from Brazil: Social class and gender-specific interaction. Int J Cardiol. 2008; 129:259-265.
24. Misra A, Misra R, Wijesuriya M. The metabolic syndrome in South Asians. In: Type 2 diabetes in South Asians: Epidemiology, risk factors and prevention (Mohan V, Rao HR, Gundu HR, eds.). Jaypee Brothers, New Delhi, India, 2006; pp. 76-96.
25. Reddy KS, Prabhakaran D, Chaturvedi V, Jeemon P, Thankappan KR, Ramakrishnan L, Mohan BV, Pandav CS, Ahmed FU, Joshi PP, Meera R, Amin RB, Ahuja RC, Das MS, Jaison TM. Methods for establishing a surveillance system for cardiovascular diseases in Indian industrial populations. Bull World Health Organ. 2006; 84:461-469.
26. Gupta R, Sarna M, Thanvi J, Rastogi P, Kaul V, Gupta VP. High prevalence of multiple coronary risk factors in Punjabi Bhatia community: Jaipur Heart Watch-3. Indian Heart J. 2004; 56:646-652.
27. Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Metabolic syndrome in urban Asian Indian adults - A population study using modified ATP III criteria. Diabetes Res Clin Pract. 2003; 60:199-204.
28. Gupta A, Gupta R, Sarna M, Rastogi S, Gupta VP, Kothari K. Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. Diabetes Res Clin Pract. 2003; 61:69-76.
29. Deepa R, Shanthirani CS, Premalatha G, Sastry NG, Mohan V. Prevalence of insulin resistance syndrome in a selected south Indian population - the Chennai urban population study-7 [CUPS-7]. Indian J Med Res. 2002; 115:118-127.
30. Okosun IS, Liao Y, Rotimi CN, Prewitt TE, Cooper RS. Abdominal adiposity and clustering of multiple factors in metabolic syndrome in White, Black and Hispanic Americans. Ann Epidemiol. 2000; 10:263-270.
31. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001; 24:683-689.
32. Chen Q, Liu Y, Huang W, Li G, Ke D. Relationship between metabolic syndrome and coronary heart disease in an aged group. Arch Gerontol Geriatr. 2007; 46:107-115.
33. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. Diabetes Care. 2005; 28:1769-1778.
34. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005; 112:3066-3072.
35. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007; 9:403-414.
36. Gupta R, Misra A, Pais P, Rastogi P, Gupta VP. Correlation of regional cardiovascular disease mortality in India with lifestyle and nutritional factors. Int J Cardiol. 2006; 108:291-300.
37. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002; 288:2709-2716.
38. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8 years follow-up of 14,719 initially healthy American women. Circulation. 2003: 107:391-397.
39. Lamarche B, Tchernof A, Mauriège P, Cantin B, Dagenais GR, Lupien PJ, Després JP. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA. 1998; 279:1955-1961.
40. Lamarche B, Cantin B, Mauriege P, Dagenais GR, Despres JP. Variability in the risk of IHD associated with moderate hypertriglyceridemia. Circulation. 1999; 100 (SUPPL 1):i739.
41. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord. 1998; 22:1145-1158.
42. Anastassios GP, Nandini AJ, Greenberg AS.Adipocytokines and Insulin Resistance. J Clin Endocrinol Metab. 2004; 89:447-452.
43. Duvnjak M, Lerotić I, Barsić N, Tomasić V, Virović Jukić L, Velagić V. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol. 2007; 13:4539-4550.
44. Arita Y, Kihara S, Ouchi N, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation. 2002; 105:2893-2898.
45. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: More than just another fat cell hormone? Diabetes Care. 2003; 26:2442-2450.
46. Feskens EJ, Tuomilehto J, Stengård JH, Pekkanen J, Nissinen A, Kromhout D. Hypertension and overweight associated with hyperinsulinaemia and glucose tolerance: A longitudinal study of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetologia. 1995; 38:839-847.
47. Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens. 1995; 13:1457-1462